For US Healthcare Professionals Only
Reduce the chaos of RSV season with BeyfortusTM (nirsevimab-alip) - protection for any infant

Power to help prevent respiratory syncytial virus (RSV) disease

Order Beyfortus Packaging Image

Start Planning for the 2024/2025 Season Today

Product images are representative of scale - actual size of packaging may be different.

ACIP AND AAP RECOMMENDED¹⁻³*

View press release
AAP, American Academy of Pediatrics; ACIP, Advisory Committee on Immunization Practices; RSV-LRTI, respiratory syncytial virus lower respiratory tract infection.
* ACIP and AAP recommend 1 dose of Beyfortus for all infants aged <8 months born during or entering their first RSV season (50 mg for infants weighing <5 kg and 100 mg for infants weighing ≥5 kg). ACIP and AAP recommend 1 dose of Beyfortus (200 mg administered as 2 intramuscular injections [2 x 100 mg]) for children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season. Refer to the most current CDC immunization schedule for additional immunization considerations.

Beyfortus® (nirsevimab-alip) is the first and only long-acting antibody indicated for the prevention of RSV lower respiratory tract disease in⁴:

Neonates and infants icon
Neonates and infants born during or entering their first RSV season
Children up to 24 months of age icon
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season
Safety icon

Demonstrated safety and
efficacy profile³

Explore Clinical Data
Syringe icon

Pre-filled syringe for
convenient administration³

Learn About Administration
Woman with infant image

Keep Up to Date With Information About Beyfortus via Email or Text

Reference: 1. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925. August 25, 2023. 2. ACIP and AAP recommendations for nirsevimab. American Academy of Pediatrics. August 15, 2023. Accessed October 7, 2023. https://publications.aap.org/redbook/resources/25379/ACIP-and-AAP-Recommendations-for-Nirsevimab 3. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.